- Issued by:
Guidance Issuing OfficeOffice of the Commissioner, Office of Policy, Legislation, and International Affairs, Office of Global Policy and Strategy, Office of Gobal Operations, Latin America Office, DO NOT USE - Terms Set to be Removed, DO NOT USE - Office of the Associate Commissioner for Regulatory Affairs
Compliance Policy Guide Sec. 230.120- Human Blood and Blood Products As Drugs is obsolete and was withdrawn on 1/30/2020.
Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All comments should be identified with the title of the guidance.